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Prolactin-releasing peptide (PrRP) was first isolated from bovine hypothalamus, and was
found to act as an endogenous ligand at the G-protein-coupled receptor 10 (GPR10 or
hGR3). Although originally named as it can affect the secretion of prolactin from anterior
pituitary cells, the potential functions for this peptide have been greatly expanded over the
past decade. Anatomical, pharmacological, and physiological studies indicate that PrRP,
signaling via the GPR10 receptor, may have a wide range of roles in neuroendocrinology;
such as in energy homeostasis, stress responses, cardiovascular regulation, and circadian
function. This review will provide the current knowledge of the PrRP and GPR10 signaling
system, its putative functions, implications for therapy, and future perspectives.
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INTRODUCTION
Seven-transmembrane-domain receptors (7TMRs) make up a
receptor superfamily related by common signaling features and
a structure that spans the cell membrane seven times. All 7TMRs
are coupled to guanine nucleotide binding proteins (G-proteins)
and, as such, are more commonly referred to as G-protein-coupled
receptors (GPCRs; Probst et al., 1992). In the human genome,
over 800 GPCRs have been annotated (>4% of the genome),
many of which since have been implicated in diverse physio-
logical roles from photoreception to olfaction, and from mood
to appetite (Fredriksson et al., 2003). This diverse functionality
infers immense therapeutic potential for the treatment of disease
and, in fact, as many as half of the currently marketed drugs
target GPCRs (Flower, 1999). Advances in genomics over the
last century, that have allowed genome-wide homology analysis,
have facilitated the discovery of so many new GPCRs. Currently
the GenBank/EMBL database has over 1000 clones of eukaryotic
GPCRs recorded, and many of the predicted receptors have no
known ligand. These are termed“orphan” GPCRs. Although many
of the GPCR genes probably correspond to homologs of sensory
olfactory receptors, which are predicted to exist in considerable
number in the genome, the remainder could encode for diverse
unknown receptors, which may play important physiological roles
Abbreviations: 7TMR, seven-transmembrane-domain receptors; ACTH, adreno-
corticotropic hormone; AP, area postrema; BL, basolateral amygdaloid nucleus;
BNST, bed nucleus of the stria terminalis; CCK, cholecystokinin-8; Ce, central amyg-
daloid nucleus; DMN, dorsomedial hypothalamic nucleus; GABA, γ-aminobutyric
acid; GPCR, G-protein-coupled receptors; GPR10, G-protein-coupled receptor
10; LH, lateral hypothalamic area; MCPO, magnocellular preoptic nucleus; MD,
mediodorsal thalamic nucleus; MPO, medial preoptic nucleus; ox, optic chiasm;
NPFF-R2, neuropeptide FF receptor 2; NPY, neuropeptide Y; NTS, nucleus of
the tractus solitarius; OLETF, Otsuka Long-Evans Tokushima Fatty; Pe, periven-
tricular hypothalamic nucleus; PrRP, prolactin-releasing peptide; PT, paratenial
thalamic nucleus; PVN, paraventricular hypothalamic nucleus; Rt, reticular nucleus
of the thalamus; SM, nucleus of the stria medullaris; SO, supraoptic hypothal-
amic nucleus; SpVe, spinal vestibular nucleus; TH, tyrosine hydroxylase; VLH,
ventrolateral hypothalamic nucleus; VLM, ventrolateral medulla.
(Buck and Axel, 1991). Due to the undoubted therapeutic potential
for the treatment of different pathologies, the discovery of ligands
by the“de-orphanization”of GPCRs and an understanding of their
physiological function is the focus of an intense research effort that
has far reaching implications for both frontier and translational
science.
One of the first GPCRs to be de-orphanized was G-protein-
coupled receptor 10 (GPR10; also known as hGR3 or UHR-1).
GPR10 was originally cloned in hypothalamic tissue using low
stringency PCR primers designed against to the highly con-
served GPCR transmembrane domains 2 and 6 (Welch et al.,
1995). The cloned receptor showed sequence similarity to the
neuropeptide Y (NPY) receptor (31% overall and 46% in the
transmembrane regions), however, it could not be activated by
either NPY or pancreatic polypeptide (Marchese et al., 1995).
This presented the scientific community with a novel problem,
in that this represented the first GPCR for which its discovery
preceded that of its endogenous ligand. Initial GPR10 localiza-
tion studies indicated high mRNA expression in the anterior
pituitary (Fujii et al., 1999). As hypothalamus derived factors
frequently play important roles in regulating anterior pituitary
function, it seemed intuitive that the natural ligand for GPR10
might exist in the hypothalamus. Using this insight, GPR10 was
finally de-orphanized by Hinuma et al. (1998), using a novel
reverse pharmacology approach. For reasons described below, the
receptor ligand was termed prolactin-releasing peptide (PrRP).
Later studies, using other in vitro heterologous expression sys-
tems, demonstrated that PrRP shows some promiscuous binding
to another RFamide peptide family receptor, neuropeptide FF
receptor 2 (NPFF-2R) (Engstrom et al., 2003; Ma et al., 2009).
However, to date, PrRP is the only ligand known to have significant
affinity for GPR10.
Initial studies showed that PrRP could stimulate prolactin
secretion from dispersed anterior pituitary cells; hence, the
peptide’s name (Hinuma et al., 1998). However since its discovery,
the importance of PrRP in the physiological regulation of
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prolactin secretion has been put in doubt (see below). Instead,
the PrRP-GPR10 signaling pathway has been implicated in a range
of other physiological systems. For example, central administra-
tion of PrRP inhibits food intake and increases energy expen-
diture in rats and mice (Lawrence et al., 2000, 2004), suggest-
ing that PrRP plays roles in the regulation of energy balance.
It also elevates circulating plasma levels of adrenocorticotropic
hormone (ACTH) level, suggesting an association of PrRP with
stress responses (Takayanagi and Onaka, 2010). Moreover, PrRP
also can affect the cardiovascular system (Samson et al., 2000)
and circadian cyclicity (Zhang et al., 2000, 2001; Lin et al.,
2002a). This article aims to review the current understanding
of the physiological roles for PrRP and GPR10 signaling in
the mammalian system, and to highlight future directions for
research.
PrRP AND GPR10 EXPRESSION
Determining the expression patterns of both receptor and ligand
gives key insight into physiological function. In situ hybridization
histology, RT-PCR, and immunohistochemical studies indicate
that PrRP is expressed in neurons of the nucleus tractus solitarius
(NTS), the ventrolateral medulla (VLM), and in the caudal por-
tion of the dorsomedial hypothalamic nucleus (DMN) (Figure 1)
(Chen et al., 1999; Maruyama et al., 1999; Ibata et al., 2000; Lee
et al., 2000). PrRP mRNA has also been found in a number of
peripheral tissues, including the adrenal gland, pancreas, placenta,
and testis (Fujii et al., 1999; Matsumoto et al., 1999a; Kalliomaki
et al., 2004).
The co-localization of PrRP with tyrosine hydroxylase (TH)
in the caudal NTS and VLM, suggests that these PrRP cells are a
subset of A2 and A1 noradrenergic neurons, respectively (Chen
et al., 1999). The highest numbers of PrRP cell bodies are found
within the NTS, and interestingly as the hypothalamus shows the
highest levels of PrRP fiber immunoreactivity, this suggested the
possible projection of PrRP from the brainstem to the hypothal-
amus (Hinuma et al., 1998; Fujii et al., 1999; Matsumoto et al.,
1999a). PrRP-immunoreactive fibers are visible in many areas
of the brain, such as the DMN, area postrema (AP), pontine
parabrachial area, preoptic areas, bed nucleus of the stria termi-
nalis (BNST), amygdala, mediodorsal nucleus of the thalamus,
septal nucleus, and ependymal linings of the ventricles and blood
vessels (Lin, 2008). One of the major projection sites is the par-
aventricular hypothalamus (PVN), where PrRP neurons appear
to synapse directly on corticotrophin-releasing hormone (CRH)
(Matsumoto et al., 1999a) and oxytocin neurons (Maruyama
et al., 1999). Cell-specific connections also have been identified on
magnocellular oxytocin/vasopressin neurons of the hypothalamic
supraoptic nucleus (Maruyama et al., 1999), somatostatin neurons
in the hypothalamic periventricular nucleus (Iijima et al., 2001),
and on catecholaminergic cells of the adrenal medulla (Fujiwara
et al., 2005).
Distribution of the GPR10 receptor has been investigated using
autoradiography, in situ hybridization, and RT-PCR (Fujii et al.,
1999; Roland et al., 1999; Ibata et al., 2000). The relative level
of expression is high in the anterior pituitary, reticular nucleus
of the thalamus (Rt), periventricular hypothalamus, DMN, AP,
and NTS; with moderate expression in the BNST, PVN, medial
preoptic area and nucleus, ventrolateral hypothalamus, stomach,
femur, and adrenal gland (Roland et al., 1999).
There is good complementarity in the localization of GPR10
receptor immunoreactive PrRP fiber staining in many brain areas
(BNST, supraoptic nucleus, PVN, DMN, and NTS). However, it is
interesting to note discrepancies in localization, which might be
surprising if GPR10 is the only receptor for PrRP. In fact, many
peptide systems have significant mismatches between the distrib-
ution of the ligand and their respective cognate receptors. Much
of this mismatch might be explained by redundancy in function,
that is a receptor will not respond if it is not in contact with the
ligand. It may be energetically convenient not to lose the expres-
sion of a receptor if there is no evolutionary pressure to do so.
Furthermore, peptides often have permissive actions and may not
function as classical transmitters at tightly regulated synaptic junc-
tions. For instance, PrRP may be released from neuronal fibers
terminating at the ventricular zones, and may enter and diffuse
within the cerebral spinal fluid (Iijima et al., 1999); or as seen
with substance P, PrRP may diffuse through the neuronal tissue
to reach distant receptor sites (Duggan et al., 1990). Although
GPR10 is considered to be the cognate receptor for PrRP, oth-
ers (perhaps currently unknown) may exist. For example, PrRP
has significant affinity at neuropeptide FF receptor 2 (NPFF-R2)
in in vitro studies, and there is potential for overlap between the
presence of PrRP and NPFF-R2 particular in the hypothalamus
and adrenal gland (Gouarderes et al., 2004). Nevertheless, the
diverse distribution profile of receptors and ligand may underlie
the diverse physiological roles played by PrRP-GPR10 signaling,
and each function needs careful investigation. In the absence of
receptor-selective antagonists, this is probably best achieved in
receptor knockout mice.
ROLE OF PrRP IN PROLACTIN SECRETION
As high expression of GPR10 is seen in the anterior pituitary, ini-
tial studies investigating the physiological action of PrRP focused
on hypophysiotropic secretion (Hinuma et al., 1998; Lin et al.,
2002b). Preliminary in vitro studies, which gave rise to the name
of the peptide, described an action of PrRP on prolactin secretion
from anterior pituitary tumor cell lines and primary cell cultures
(Hinuma et al., 1998). Subsequent studies investigating the rel-
evance of PrRP in vivo as a central mediator of prolactin release
were controversial, with positive results being reliant on high intra-
venous PrRP doses administered during specific phases of female
rat estrous cycle (Matsumoto et al., 1999b). Other studies demon-
strated no prolactin release following central administration of
PrRP (Matsumoto et al., 2000; Seal et al., 2002). Moreover, as
no PrRP immunoreactivity is found in the median eminence or
in hypophysiotropic cells of the hypothalamus (Matsumoto et al.,
1999a; Maruyama et al., 2001), classically associated with the secre-
tion of pituitary hormones, the question remains how does PrRP
access the pituitary? PrRP may act upon the anterior pituitary as
a hormone secreted from peripheral tissues (adrenal, pancreas,
testis, placenta), or by an indirect central mechanism possibly via
hypophysiotropic neurons (Morales and Sawchenko, 2003). This
is a strong possibility, since central administration of PrRP can
affect a number of anterior pituitary hormones (Seal et al., 2002).
Interestingly, in fish and amphibians, PrRP fibers project to and
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FIGURE 1 | Schematic drawings showing the neuronal distribution
of PrRP and GPR10 receptor in the Paxions andWatson rat brain
atlas (Paxinos andWatson, 1998; Sun et al., 2005). Blue areas
represent PrRP-immunopositive nerve fibers; black checkers represent
PrRP cells bodies; green areas represent GPR10 expression; and red
areas represent overlap of PrRP and GPR10 expression. AP, area
postrema; BL, basolateral amygdaloid nucleus; BNST, bed nucleus of the
stria terminalis; Ce, central amygdaloid nucleus; DMN, dorsomedial
hypothalamic nucleus; LH, lateral hypothalamic area; MCPO,
magnocellular preoptic nucleus; MD, mediodorsal thalamic nucleus;
MPO, medial preoptic nucleus; ox, optic chiasm; PVN, paraventricular
hypothalamic nucleus; Pe, periventricular hypothalamic nucleus; PT,
paratenial thalamic nucleus; Rt, reticular thalamic nucleus; SM, nucleus
of the stria medullaris; SO, supraoptic hypothalamic nucleus; NTS,
nucleus of the tractus solitarius; SpVe, spinal vestibular nucleus; VLH,
ventrolateral hypothalamic nucleus.
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terminate on prolactin-producing cells of the pituitary and sys-
temic injection of PrRP into rainbow trout causes a release in
prolactin and somatolactin (Moriyama et al., 2002; Seale et al.,
2002; Sakamoto et al., 2006). PrRP may, therefore, represent an
ancient factor for the direct regulation of prolactin secretion that is
now evolutionary redundant in this function in higher mammals.
Thus, the name, PrRP, may represent a misnomer, as research over
the past decade has implicated this signaling pathway in alternative
physiological systems.
CONSERVED FUNCTION OF PrRP AND GPR10 SIGNALING IN
FEEDING BEHAVIOR
Prolactin-releasing peptide belongs to the RFamide neuropep-
tide family (Osugi et al., 2006). Although this family impacts
on a diverse range of physiological functions, almost all have
been shown to modulate food intake (Bechtold and Luckman,
2007). This involvement of the RFamides in feeding behavior
has been demonstrated across most animal taxa, including coe-
lenterates, mollusks, amphibians, birds, and mammals, suggesting
an evolutionary conserved role in energy homeostasis (Dockray,
2004).
Numerous studies suggest a pivotal role of PrRP in the homeo-
static regulation of feeding and energy balance. Evidence from our
group has shown that central administration of PrRP decreases
feeding and body weight gain in rats and mice without causing
adverse effects (Lawrence et al., 2000, 2002; Bechtold and Luck-
man, 2006), and that PrRP mRNA in the DMN, NTS, and VLM
is downregulated in states of negative energy balance (Lawrence
et al., 2000). Importantly, these central anorexic actions of PrRP
are not present in mice (Bechtold and Luckman, 2006) or rats
(Watanabe et al., 2005) that lack functional expression of GPR10,
highlighting the significance of endogenous PrRP-GPR10 signal-
ing in food intake. The significance of this system to energy
homeostasis generally is validated further by the obese and hyper-
phagic phenotypes of both PrRP−/− and GPR10−/−null mice (Gu
et al., 2004; Takayanagi et al., 2008).
As PrRP induces hypophagia without evoking a conditioned
taste aversion or disrupting the normal behavioral satiety sequence
(Lawrence et al., 2002), it seems likely that PrRP-GPR10 signaling
plays an integral part of the brain’s endogenous appetitive neuro-
chemistry. In fact, PrRP induces a significant temporal advance-
ment in the behavioral satiety sequence, an affect associated with
natural satiety factors like cholecystokinin-8 (CCK) (Lawrence
et al., 2002). Furthermore, experiments with PrRP−/−mice or
PrRP-neutralizing antibodies, in the laboratory of Tatsushi Onaka,
show that PrRP regulates meal size rather than meal frequency,
indicating that PrRP may mediate appetite by direct actions on
satiation (Takayanagi et al., 2008). As the brainstem medulla
oblongata and, in particular, the NTS receives extensive gastroin-
testinal vagal inputs, these PrRP neurons are an obvious candidate
for a role in gut-brain signaling. CCK is released from enteroen-
docrine cells in response to a meal, and acts via the CCK1 receptor
on vagal afferent neurons which terminate in the NTS (Saper,
2004). PrRP neurons localized in both the NTS and the VLM
show strong functional activation in response to anorexic doses of
CCK (Lawrence et al., 2002). Central administration of PrRP elic-
its a similar pattern of neuronal c-Fos protein expression as that
observed following intraperitoneal administration of CCK (Luck-
man, 1992; Lawrence et al., 2002; Bechtold and Luckman, 2006),
and the anorexic effects of CCK are impaired in both PrRP−/− and
GPR10−/−null mice (Bechtold and Luckman, 2006; Takayanagi
et al., 2008).
The downstream actions of PrRP neurons within the brainstem
remain to be clarified. However, PrRP receptor is present in the
dorsal vagal complex (Roland et al., 1999; Ibata et al., 2000) and
PrRP can act pre-synaptically to affect the firing of preganglionic
vagal efferents involved in regulating gut function (Morales and
Sawchenko, 2003). Thus, although not proven, it is likely that
PrRP-GPR10 signaling within the dorsal vagal complex may medi-
ate the effects of CCK on the parasympathetic regulation of gut
motility and secretion. The sensation of satiety, and integration
with descending motor pathways to regulate feeding, requires inte-
gration with higher brain centers. PrRP-immunoreactive fibers
and GPR10 mRNA expression have been demonstrated in a num-
ber of hypothalamic nuclei (Fujii et al., 1999; Maruyama et al.,
1999; Roland et al., 1999; Ibata et al., 2000; Lee et al., 2000). In par-
ticular, PrRP-containing neurons in the NTS project directly to the
PVN (Onaka, 2004), where neurons containing CRH or oxytocin
possess PrRP receptor (Lin et al., 2002a; Takayanagi and Onaka,
2010). Though anorexic doses of PrRP activate neurons express-
ing CRH or oxytocin in the PVN (Bechtold and Luckman, 2006;
Mera et al., 2006), it is difficult to relate this specifically to satiety
signaling, as these neurons may equally be involved in responses
to stress (see below). However, PrRP-induced anorexia is attenu-
ated by CRH receptor antagonists (Bechtold and Luckman, 2006),
while oxytocin receptor antagonists attenuate the anorexic actions
of both PrRP and CCK (Olson et al., 1991; Blevins et al., 2003).
Further work will be required to dissect the relative importance
of ascending PrRP pathways on satiety and stress-related stimuli.
Additional consideration for the role of DMN PrRP neurons in
the regulation of feeding behavior is needed also. However, our
working model is that PrRP-GPR10 signaling mediates the CCK-
vagal regulation of gut function following a meal at the level of the
dorsal vagal complex in the brainstem. Further integration with
higher brain centers is achieved through the projection of PrRP
neurons to the hypothalamus. This may include CRH and oxy-
tocin neurons of the PVN, the latter, at least, having an accepted
role in the descending fine regulation of the dorsal vagal com-
plex and feeding control (Samson et al., 2000; Yamada et al., 2009;
Onaka et al., 2010).
ENERGY HOMEOSTASIS
Though the evidence for PrRP-GPR10 functioning in satiation is
strong, this does not infer a role in overall energy balance, and
an interaction with other metabolic regulators might be expected.
We have shown that the expression of PrRP is down regulated
in situation where the animal is in real (e.g., fasting or lactation)
or in perceived (e.g., Zucker rat) negative energy balance (Ellacott
et al., 2002). That is, situations which correlate with reduced lep-
tin signaling. Leptin is an adipose-derived hormone, that signals
levels of peripheral fat storage to the brain to regulate long-term
metabolism (Denver et al., 2011). Immunohistochemical studies
have suggested that PrRP neurons (and TH-positive cells) in the
brainstem and hypothalamus of the rat express leptin receptors
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and, thus, that there is a direct cellular effect of the hormone
(Hay-Schmidt et al., 2001; Ellacott et al., 2002). However, a more
recent paper failed to co-localize leptin receptor in brainstem PrRP
neurons of the mouse (Garfield et al., 2012). Leptin induces the
expression of phosphorylated signal transducer and activator of
transcription protein 3 (pSTAT3) in PrRP neurons, especially those
in the DMH (Takayanagi et al.,2008). Central co-administration of
PrRP and leptin results in augmented hypophagia and body weight
loss (Ellacott et al., 2002), and the hypophagic effects of leptin are
impaired in PrRP−/− (Takayanagi et al., 2008) and GPR10−/− null
mice (our unpublished results). PrRP-GPR10 clearly has a role in
the response to leptin, but whether this is due to a direct or indirect
effect of leptin on PrRP neurons remains to be determined.
The maintenance of energy homeostasis involves the balance
of both energy intake and energy expenditure. Interestingly pair-
feeding studies indicate that the reduced weight gain measured in
rats treated with PrRP is not accounted for solely by a reduction
in food intake, suggesting that PrRP also affects energy expendi-
ture (Lawrence et al., 2000, 2004). PrRP administration acutely
increases body temperature, O2 consumption, and UCP-1 expres-
sion of brown adipose tissue in rats (long before any effect on body
weight), suggesting direct modulation by PrRP of energy expen-
diture (Lawrence et al., 2004). Furthermore, GPR10−/− knockout
mice exhibit a much lower basal metabolic rate, when compared
with wild-type mice (our unpublished data), which likely con-
tributes to the obese phenotype of these animals (Gu et al., 2004).
Thus, PrRP-GPR10 signaling can induce energy expenditure and
thermogenesis, which is interesting considering the known role of
the DMN in thermoregulation (Willette et al., 1984; Aicher et al.,
1995; Horiuchi et al., 2002). In addition, PrRP may play a role in
mediating energy consumption under stressful conditions, as the
increase oxygen consumption seen in response to stressful stimuli
is attenuated in PrRP−/− mice (Onaka et al., 2010).
ROLES OF PrRP AND GPR10 SIGNALING IN THE CONTROL OF
STRESS RESPONSES
Brain nuclei expressing PrRP and GPR10, such as in the medulla
oblongata and the hypothalamus, have been implicated in medi-
ating stress responses (Onaka, 2004). PrRP neurons within these
regions respond to a variety of stressful stimuli including body
restraint, fear conditioning (Zhu and Onaka, 2003), footstock,
hemorrhage (Uchida et al., 2010), and inflammatory stress (Mera
et al., 2006). PrRP neurons may, therefore, play an important role
in the neuroendocrine response to stress.
Retro-grade tracing of the PrRP neurons innervating the PVN
indicates that the fibers originate within the VLM and NTS, where
they co-localizes with noradrenaline in the A1 and A2 neuronal
populations, respectively (Chen et al., 1999; Minami et al., 1999;
Roland et al., 1999; Morales et al., 2000; Maruyama et al., 2001).
These noradrenergic neurons are well known mediators of stress in
the central nervous system. Models of emotional stress, including
conditioned fear stimulation and water immersion/restraint acti-
vate medullary PrRP neurons and increases PrRP mRNA expres-
sion (Maruyama et al., 2001; Morales and Sawchenko, 2003; Zhu
and Onaka, 2003). Interestingly, PrRP and noradrenaline, which
co-localize in A1/A2 cells, act synergistically to induce systemic
ACTH release (Maruyama et al., 2001).
One way in which PrRP may influence stress response is by the
dense network of PrRP clustered on CRH and oxytocin neurons in
the PVN and BNST (Iijima et al., 1999; Maruyama et al., 1999; Ibata
et al., 2000). Central administration of PrRP dramatically increases
c-Fos expression in CRH neurons in the PVN, an effect that results
in the concomitant release of ACTH, oxytocin, and corticosterone
into the systemic circulation (Matsumoto et al., 2000; Seal et al.,
2002). Importantly, blockade of endogenous PrRP signaling by
administration of PrRP neutralizing antibodies attenuates stress
induced activation of PVN neurons and reduces systemic oxytocin
release (Zhu and Onaka, 2003; Mera et al., 2006).
Although contacts are seen between PrRP fibers and CRH neu-
rons in the PVN (Matsumoto et al., 2000), their relative paucity
suggests that these synapses are unlikely to be responsible for
the entire modulation of CRH neurons in the PVN. Double
in situ hybridization shows that the majority of cells expressing
GPR10 in the PVN are in fact CRH-negative, whereas GPR10
is co-expressed extensively with CRH in the BNST (Lin et al.,
2002b). The BNST not only receives extensive PrRP nerve fibers
(Maruyama et al., 1999), it is involved with stress responses via a
direct modulation of the PVN (Palkovits et al., 1980; Lin et al.,
2002b). It, therefore, seems possible that PrRP may also regu-
late CRH neurons in the PVN indirectly via the BNST. These
results suggest that whether directly or indirectly, PrRP is a potent
stimulator of CRH neurons in the PVN, inferring access to the
hypothalamic–pituitary–adrenal axial control of stress.
Stressful stimuli affect food intake and energy expenditure,
while food intake and energy expenditure affect stress responses
(Kawakami et al., 2008). For instance PrRP−/− mice show a
reduced increase in oxygen consumption following stressful stim-
uli (Onaka et al., 2010). It seems tempting to suggest that PrRP
may modulate food intake in times of stress. Although only spec-
ulative further examination of this hypothesis using conditional
transgenic mice for PrRP and GPR10 could help shed light on this
theory.
EFFECTS OF PrRP AND GPR10 ON BLOOD PRESSURE
Central injection of PrRP results in a significant increase in blood
pressure and cardiovascular output in conscious, unrestrained rats
(Samson et al., 2000). Numerous studies describe integral roles
played by the NTS, AP, and VLM in mediating cardiovascular
function (Yamada et al., 2009). It seems likely that PrRP neu-
rons in these regions may be involved. The NTS and AP receive
visceral and hormonal information from peripheral cardiovascu-
lar sites (Aicher et al., 1995), so PrRP and GPR10 in these sites
may be in a position to modify the ascending and descending
efferent connections mediating blood pressure homeostasis (Wil-
lette et al., 1984; Aicher et al., 1995). Site specific administration
of PrRP directly into the caudal VLM (where a population of
PrRP neurons are localized) results in a dose-dependent increase
in mean arterial blood pressure, heart rate, and renal sympathetic
activity (Horiuchi et al., 2002). Interestingly however, PrRP has
no effect when injected directly into the rostral VLM, AP, or the
NTS. How PrRP modulates blood pressure homeostasis in an area
of minimal GPR10 receptor expression such as the VLM and not
in regions of high receptor expression such as the AP and NTS
remains enigmatic (Chen et al., 1999; Roland et al., 1999).
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Although the mechanisms underlying the pressor effects of
PrRP are undefined, a recent study by Yamada et al. (2009) sug-
gests the involvement of CRH neurons in the PVN. PrRP neurons
from the VLM project to the PVN where they synapse on CRH
positive cells. Central CRH has a known effect of elevating blood
pressure in response to stressors (i.e., CRH stimulates sympa-
thetic nerves via the CRH1 receptor) (Vale et al., 1983; Spina et al.,
2000). Yamada et al. (2009) show that pressor- and tachycardia-
inducing doses of PrRP activate oxytocin-, vasopressin-, and CRH-
producing neurons in the PVN. Furthermore, the elevation of
blood pressure and heart rate elicited by PrRP administration
are completely suppressed by treatment with a CRH antagonist.
PrRP neurons in the VLM may, therefore, mediate CRH release
to regulate the cardiovascular system via the sympathetic nervous
system.
Finally, the receptor mediating PrRP pressor and tachycardia
effects remains unclear. Epidemiological human studies show an
association of polymorphisms in the GPR10 receptor with blood
pressure, thus implying a potential role of the GPR10 receptor in
blood pressure regulation (Bhattacharyya et al., 2003). Contrast-
ingly, PrRP can still elicit effects on mean arterial blood pressure
and heart rate in Otsuka Long-Evans Tokushima Fatty (OLETF)
rat strain, in which the GRP10 receptor gene is naturally mutated
(Ma et al., 2009). Instead, PrRP effects were blocked by admin-
istration of the NPFF-2R antagonist, RF9, suggesting that PrRP
may modulate blood pressure homeostasis via the NPFF-2R (Ma
et al., 2009). It will be useful to follow up these studies using
other models since neither the OLETF rat (which has at least one
other natural mutation, in the CCK1 receptor gene), nor the R9
antagonist, are the best tools available. Certainly, if unwanted car-
diovascular effects of PrRP are mediated solely by the NPFF-R2,
there could be therapeutic potential for selective GPR10 agonists
as drug targets other metabolic diseases.
EFFECTS OF PrRP AND GPR10 CIRCADIAN RHYTHMICITY
AND SLEEP REGULATION
The expression of GPR10 in particular brain regions, including
the preoptic area, the histaminergic ventral tuberomammillary
nucleus, the noradrenergic locus ceruleus, serotonergic dorsal
raphe, and suprachiasmatic nucleus suggested that PrRP-GPR10
signaling may play a part in circadian rhythmicity and/or sleep reg-
ulation (Chen et al., 1999; Roland et al., 1999). The relative impor-
tance of PrRP-GPR10 signaling in each of these specific nuclei is yet
to be investigated, however, a wealth of literature exists implicating
an integral role in sleep and arousal (for reviews, see Suntsova et al.,
2009; Szymusiak, 2010; Brown et al., 2012; Murillo-Rodriguez
et al., 2012). One region of particular interest, which has a high
GPR10 receptor expression, is the Rt (Roland et al., 1999). The Rt
is predominantly GABAergic and acts as a gateway for ascending
inputs into the cortex that regulate the transition into sleep (Steri-
ade, 2005; Timofeev and Chauvette, 2011). Central administration
of PrRP is known to modulate sleep oscillation, and promote rapid
and prolonged arousal (Zhang et al., 2000; Lin et al., 2002a). Fur-
thermore, electrophysiological experiments on brain slices show
that administration of PrRP attenuates oscillatory activity gener-
ated in the Rt,a phenomena that could underlie PrRP’s modulation
of circadian and sleep regulation (Lin et al., 2002a).
FUTURE PERSPECTIVES
Since the de-orphanization of GPR10, research into the phys-
iological roles of PrRP neurotransmission has been varied
and exciting. The PrRP peptide is conserved among species
(fish, amphibians, birds, and mammals), pointing toward it
seems both primitive and important function (Dockray, 2004;
Bechtold and Luckman, 2007). Research into the physiolog-
ical roles of PrRP has evolved from the initial observations
as a “PrRP” (perhaps resulting in a misnomer) to a multi-
functional protein integral to a number of functions. Given
the current understanding of the PrRP-GPR10, it seems likely
that this ancient signaling system may act in times of stress
to regulate feeding behavior, induce energy expenditure and
increased cardiac output, heighten arousal, and allow the sys-
temic release of endocrine factors. It is possible that, in mam-
malian species, some of these functions have been modified
more specifically, for example into a role in satiation and energy
regulation.
To further examine the importance of PrRP-GPR10 signaling a
number of outstanding questions need to be addressed.
WHAT ARE THE RELATIVE IMPORTANCE OF THE DIFFERENT
POPULATIONS OF PrRP-PRODUCING CELLS IN THE BRAINSTEM,
HYPOTHALAMUS, AND IN PERIPHERAL TISSUES?
This review has highlighted potential differential roles for the
PrRP-expressing neuronal populations. Although currently only
speculative, it seems that the VLM may play a specific role in the
pressor effects of PrRP (Horiuchi et al., 2002); whereas, the NTS
appears important in mediating CCK’s effect on satiation (Bech-
told and Luckman, 2006). Interestingly, a recent study has shown
that systemic CCK acts to attenuate liver gluconeogenesis indepen-
dently of insulin production (Cheung et al., 2009). Importantly,
the effect requires the integration of a gut–brain–liver axis; effects
that could be centrally mediated by CCK responsive PrRP neurons
in the NTS.
Further speculation arises over the function of the DMN
PrRP population. Takayanagi and Onaka (2010) show signifi-
cant pSTAT3 co-expression following leptin administration in
DMN, suggesting that DMN PrRP neurons are responsive to
leptin. Although there is little doubt of the importance of lep-
tin receptor in energy homeostasis, recent research has specifi-
cally identified leptin responsive neurons in the DMN as medi-
ators of adaptive thermogenesis (Enriori et al., 2011; Bech-
told et al., 2012). As adaptive thermogenesis and the neuronal
circuitry innervating brown adipose tissue is currently topical
in the domain of anti-obesity therapeutics, it is important to
investigate whether the PrRP neurons play a part. Also, both
PrRP and GPR10 are expressed in peripheral tissues (Roland
et al., 1999). Nothing is known about the importance of periph-
eral PrRP-GPR10 signaling, and the exploration of these inter-
actions could be vital to the development of viable GPR10
therapeutics.
The recent advancements in the generation of conditional
transgenic mice, makes finding the answers to these questions pos-
sible. For instance the generation of mice conditionally expressing
PrRP under the control of different promoters will allow the
genetic dissection of specific populations.
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WHAT ARE THE DOWNSTREAM AND UPSTREAM TARGETS OF
PrRP – GPR10 SIGNALING?
Understanding the neurochemical make up of PrRP target neurons
will help to further define and dissect out the relative importance
of each neuronal population. Recent advancements in antero-
and retro-grade labeling using Cre recombinase specific aden-
oviral vectors could advance our understanding of how specific
PrRP neuronal population integrate into both the local and global
neuronal circuits (Gautron et al., 2010).
There is as a potential caveat with much of the work already
achieved in understanding PrRP-GPR10 signaling. As mentioned
above, there is some divergence, at least in the mammalian
system, between PrRP-expressing nerve fibers and the location
of GPR10 receptors. Thus, an element of deliberation must be
taken to understanding studies whereby PrRP is administered
globally into the brain and at non-physiological doses, as this
could be activating redundant receptors. Although this problem
may be minimal, the use of conditional transgenic animals, con-
ditional viral vectors, and the development of selective GPR10
agonists/antagonists will greatly enhance our understanding of
this important neurotransmitter system. Although much of the
ground work has been established, there is still much to learn
about PrRP-GPR10 signaling and its definitive roles in the nervous
system.
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